Valion Bio, Inc. (VBIO)
1.17
-0.06
(-4.88%)
USD |
NASDAQ |
Oct 16, 16:00
1.14
-0.03
(-2.56%)
After-Hours: 20:00
Valion Bio Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2025 | -99.32% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | -132.8% |
| September 30, 2024 | 34.13% |
| June 30, 2024 | 20.71% |
| March 31, 2024 | 49.70% |
| December 31, 2023 | 0.84% |
| September 30, 2023 | 38.30% |
| June 30, 2023 | 35.40% |
| March 31, 2023 | 29.52% |
| December 31, 2022 | 9.80% |
| Date | Value |
|---|---|
| September 30, 2022 | 12.58% |
| June 30, 2022 | 23.30% |
| March 31, 2022 | 15.89% |
| December 31, 2021 | -1.03% |
| September 30, 2021 | -10.11% |
| June 30, 2021 | -13.06% |
| March 31, 2021 | 6.19% |
| December 31, 2020 | -22.64% |
| September 30, 2020 | -23.87% |
| June 30, 2020 | -44.35% |
| March 31, 2020 | -29.51% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Outlook Therapeutics, Inc. | -254.0% |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -176.8% |
| Return on Assets | -103.0% |
| Return on Invested Capital | -113.7% |
| Return on Net Operating Assets | -132.3% |